← Writing

The Curious Case of ARPdV

Alzheimer'sAPOEgeneticscase study

Aliria Rosa Piedrahita de Villegas was a Colombian woman with the (in)famous PSEN1 E280A mutation — carried by the Colombian kindred — as well as a carrier of both copies of the APOE3 Christchurch mutation [1]. By every measure of prediction, she should have developed Alzheimer's Disease in her 40s [2]. Instead, she lived entirely dementia-free into her 70s, and was able to recognize all her grandchildren by name at her 70th birthday [1]. This is a paradox researchers have puzzled over: how was she able to escape the symptoms of Alzheimer's despite being overwhelmingly likely to develop them? Her clinical case matters for understanding neuronal death because it shows that severe amyloid pathology — the most common biomarker of Alzheimer's — does not inevitably produce early cognitive decline, since downstream tau pathology and neurodegeneration can be limited [1, 3].

The Expected Cascade

For most carriers of the PSEN1 E280A mutation, the course Alzheimer's Disease takes is very predictable, since PSEN1 E280A is a strong autosomal-dominant mutation affecting the largest documented group of carriers — known as the Colombian kindred [2, 4]. This mutation increases Aβ production by altering how γ-secretase processes APP. PSEN1 encodes the catalytic core of γ-secretase, and this mutation alters its activity to increase the production or relative abundance of longer, more aggregation-prone Aβ peptides such as Aβ42 [5, 6].

These peptides aggregate into oligomers and plaques and disrupt the extracellular environment downstream [7]. Amyloid aggregation is a core upstream feature of Alzheimer's disease, but cognitive decline and neurodegeneration are often more closely associated with tau pathology, synaptic degeneration, and metabolic dysfunction than with amyloid burden alone [8, 9]. As tau accumulates in neurons, it disrupts synapses and axons [8], compounded by metabolic problems reflected in FDG-PET hypometabolism, a biomarker of synaptic and neuronal dysfunction [10]. Synaptic degeneration and neuronal loss track closely with cognitive symptoms [8], from which clinical symptoms emerge. Aliria's case interrupts this sequence between amyloid accumulation and widespread tau pathology — the cellular reason her cognition was preserved [1, 3].

Amyloid Paradox

Aliria was not protected from Alzheimer's because she lacked its defining pathology, amyloid aggregation [1] — instead, she had a much higher amyloid burden than other patients. Her mean cortical-to-cerebellar PiB DVR (which measures Aβ through PET imaging) was 1.96; comparatively, average carriers of the same mutation who became symptomatic decades earlier had PiB DVRs of 1.49–1.60 [1].

This creates the amyloid paradox, which fundamentally changed how scientists think about Alzheimer's. If amyloid accumulation alone were sufficient to cause neuron death, Aliria should have exhibited the expected cascade described above. Instead, downstream phenomena such as tau pathology were not observed at high levels [1, 3]. Aliria's case does not make amyloid an irrelevant biomarker for Alzheimer's — it does accumulate years before clinical onset and remains a core upstream feature of the disease [10, 11] — but it does suggest that the presence of amyloid alone is not sufficient to determine whether neurons fail and when cognition breaks down [1]. The explanation, then, must lie in the downstream consequences of amyloid.

Tau and the Downstream Cascade

In contrast to her amyloid data, tau-PET testing showed that her tau pathology was restricted to the medial temporal and occipital lobes (standard for early dementia patients) and was much lower across the cortex than in other patients carrying the same mutation [1, 3]. FDG-PET exams, which test cerebral glucose metabolism as a marker of synaptic function, showed her glucose metabolism was much better than that of younger PSEN1 mutation carriers with mild cognitive impairment (MCI) [1]. This was especially true in the precuneus, an area of the parietal lobe most differentially affected in Alzheimer's, which is striking given that it was preserved in her case [1]. Heterozygous APOE3ch carriers also show relatively preserved metabolic activity in areas typically involved in Alzheimer's disease [12].

This provides a more concrete explanation for Aliria's surprising cognitive preservation. Tau burden and neurodegeneration generally correlate more closely with cognitive impairment than amyloid burden does, and tau PET is a stronger marker of clinical severity and future cognitive decline than amyloid PET in many studies [9, 13]. First, tau pathology spreads much more through functionally connected brain regions — "trans-synaptic spread" [14]. Tau is released from neurons through exosomes and membrane release, taken up by connected neurons, and causes misfolding of normal tau in the next cell [15, 16]. Braak's work showed that neurofibrillary tangles spread in a very predictable way that follows anatomical and functional connections, which is more damaging; plaques, by contrast, spread in a much more random pattern. Second, tau correlates more strongly with regional cognitive symptoms than amyloid does [9, 11] — there is substantial evidence that neurofibrillary tangles in specific regions correlate significantly with cognitive impairment, for example tau in language regions causing language impairment and tau in visuospatial regions causing visuospatial deficits [9], a relationship not observed for amyloid. Third, tau is more directly linked to synaptic dysfunction and axonal injury [8], because tau is normally localized to axons to stabilize microtubules; when hyperphosphorylated, it detaches from microtubules, which destabilizes them.

APOE3 Christchurch Modifier

Aliria was also found to be homozygous for the APOE3 Christchurch mutation, which may have altered her brain's response to amyloid and delayed the downstream consequences of amyloid pathology [1]. The R136S mutation lies in the receptor-binding region of APOE — the positively charged domain that binds negatively charged cell-surface molecules [1, 17]. This region mediates APOE's interaction with heparan sulfate proteoglycans (HSPGs), the LDL receptor, and the LDL receptor-related protein [17]. The Christchurch mutation replaces a positively charged arginine with an uncharged serine, weakening the electrostatic interaction with HSPGs in particular [1, 18]. HSPGs act as uptake receptors for many misfolded proteins [14].

For tau specifically, the 3-O-sulfation pattern of heparan sulfate helps mediate the binding and cellular internalization of tau aggregates [19, 20]. Pathological tau binds to HSPGs on the surface of recipient neurons [14]. APOE3 Christchurch is proposed to weaken pathological APOE–HSPG interactions, and experimental models link weaker APOE3ch–HSPG binding to enhanced myeloid-cell phagocytosis and degradation of tau aggregates [1, 18]. In mouse models, APOE3ch reduces tau pathology via this weaker APOE3ch–HSPG binding [18]. APOE3ch microglia also show much higher phagocytic activity than APOE3 microglia, allowing them to keep clearing phosphorylated tau [18, 21]. In the postmortem study of Aliria's brain, there was much higher APOE expression in her frontal cortex and hippocampus, where there was less neuron death, and lower APOE expression in her occipital cortex, where there was severe tau pathology and substantial neuron death [3]. One potential mechanism explaining the gap between amyloid and tau pathology, then, is that reducing APOE–HSPG binding disables one of the main ways tau travels through the brain [14, 18].

Glial, Inflammation, and Cell-Death Pathways

APOE is produced primarily by glia, so a mutation in APOE affects the glial environment as well, linking it to Alzheimer's [17]. Glia support neuron survival in several ways: microglia clear protein aggregates like p-tau and synaptic debris [8, 22], and astrocytes regulate metabolism broadly [17]. Glia therefore help determine whether amyloid pathology leads to tau spread — a mouse study found that TREM2 knockout and microglial ablation dramatically increased tau spreading around plaques [22]. There is evidence that APOE3ch protects neurons by keeping the surrounding glial environment alive and functional in three main ways. First, in human iPSC-derived models, APOE3ch microglia were more resistant to Aβ-induced lipid peroxidation and ferroptosis, helping preserve phagocytosis and p-tau clearance [21]. Second, APOE3ch microglia exhibit a reduced inflammatory response compared with APOE3 microglia in PSEN1-mutant neuron co-cultures [21], meaning less chronic stress on glia and a lower likelihood of glial cell death. Third, in Aliria's autopsy, astrocytes retained their homeostatic markers in areas of high APOE3ch expression, while becoming more neurotoxic in areas of low expression [3]. Altogether, there is reasonable evidence that Aliria's mutations allowed for a healthier glial environment that helped prevent tau pathology.

Alternative Explanations

There are several alternative or complementary explanations that do not rely on APOE3ch. First, other genetic modifiers: a second resilient case was recently discovered — a man heterozygous for a rare RELN variant (Reelin-COLBOS) who remained cognitively intact until 67 even though he had extremely elevated amyloid levels — showing that an entirely different gene can produce a similar phenotype [23]. Cochran et al. further emphasize that genetic background contributes independently of APOE3ch [24]. Aliria's protection may therefore be partially attributable to other, unmeasured modifiers, making the APOE3ch story correlational rather than fully causal.

Second, even within her Colombian kindred, age of onset varies substantially — median onset for MCI is 44 years and for dementia is 49 years, but some people reach their 60s without APOE3ch [2, 4]. Aliria's thirty-year delay may reflect variation on top of a host of other factors, with the APOE3ch effect layered on top.

Third, vascular contributions are also important. Postmortem analysis of Aliria's brain found cortical microinfarcts, arteriosclerosis, and perivascular space enlargement, but less cerebral amyloid angiopathy (CAA) than typical PSEN1 E280A carriers, with CAA restricted to leptomeningeal vessels of the cerebellum [3]. CAA contributes to Alzheimer's cognitive decline through mechanisms including microbleeds, blood–brain barrier disruption, and impaired perivascular drainage, so reduced CAA could be a major protective mechanism operating independently of the tau-spread hypothesis.

Fourth, cell-intrinsic resilience may also have contributed. Neurons are not passive victims of amyloid and tau; their survival also depends on internal stress-response systems like mitochondrial function, calcium regulation, proteostasis, autophagy, and synaptic repair. If neurons had a stronger capacity to maintain energy production and clear misfolded proteins, they might have resisted degeneration even under severe amyloid pathology. This is hard to prove, since glial protection and neuronal resilience are difficult to separate experimentally — APOE3ch may have protected neurons indirectly by maintaining a healthier glial environment, or certain neuronal populations may have possessed intrinsic properties enhancing tolerance to proteotoxic and metabolic stress. These explanations are not mutually exclusive.

Limitations

Aliria's case is a singular, surprising clinical case, and causality and mechanism can never be fully established from just one person [1, 21]. It cannot prove that the APOE3 Christchurch mutation causes resilience to Alzheimer's — there are many unmeasurable factors, like other mutations, environmental exposures, and lifestyle, that may have shaped this unique case. Indeed, Aliria's case is particularly exaggerated: other heterozygous APOE3ch carriers experience only a partial delay of cognitive symptoms, not a thirty-year delay [12]. A later analysis of 27 PSEN1 E280A carriers heterozygous for APOE3 Christchurch found a more modest delay, with median cognitive impairment onset at 52 years versus 47 years in matched noncarriers [12]. The authors emphasized limitations from the small number of APOE3ch carriers and the genetic-isolate nature of the cohort, noting that the findings may not generalize to sporadic Alzheimer's disease or other populations [12] — perhaps suggesting that Aliria's homozygosity for APOE3ch is important, though this is not certain. There is also a basic tension in explaining mechanisms through mouse models: it is impossible to replicate three decades of in vivo human brain aging, so that part will always remain somewhat uncertain [18, 21].

Conclusion

Ultimately, Aliria recognizing her grandchildren at her seventieth birthday is a clinical outlier, to say the least. This was not because her brain had been spared Alzheimer's pathology, but because the expected cascade was interrupted at some point [1, 3]. Likely, this interruption relates to her other mutation — APOE3ch reducing APOE–HSPG binding and keeping microglia alive and functional [18, 21] — severing the bridge between upstream cellular pathology and the actual death of neurons, and allowing her to preserve her memory. Her case points future therapeutic efforts not just toward amyloid removal, but also toward interventions that sever this cascade, such as by mimicking the protective effects of the APOE3ch mutation [18, 21].

References

  1. Arboleda-Velasquez, J. F., Lopera, F., O'Hare, M., Delgado-Tirado, S., Marino, C., Chmielewska, N., Saez-Torres, K. L., Amarnani, D., Schultz, A. P., Sperling, R. A., et al. (2019). Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 25(11), 1680–1683.
  2. Acosta-Baena, N., Sepulveda-Falla, D., Lopera-Gómez, C. M., Jaramillo-Elorza, M. C., Moreno, S., Aguirre-Acevedo, D. C., Saldarriaga, A., & Lopera, F. (2011). Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. The Lancet Neurology, 10(3), 213–220.
  3. Sepulveda-Falla, D., Sanchez, J. S., Almeida, M. C., Boassa, D., Acosta-Uribe, J., Vila-Castelar, C., Ramirez-Gomez, L., Baena, A., Aguillon, D., Villalba-Moreno, N. D., et al. (2022). Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathologica, 144(3), 589–601.
  4. Aguirre-Acevedo, D. C., Lopera, F., Henao, E., Tirado, V., Muñoz, C., Giraldo, M., Bangdiwala, S. I., Reiman, E. M., Tariot, P. N., Langbaum, J. B., Quiroz, Y. T., & Jaimes, F. (2016). Cognitive decline in a Colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study. JAMA Neurology, 73(4), 431–438.
  5. Lessard, C. B., Rodriguez, E., Wagg, L. K., Jiao, H., Ladd, T. B., Cruz, P. E., Carter, R. M., Petrucelli, L., Felsenstein, K. M., Robles, M. T., et al. (2024). Functional variations in γ-secretase activity are essential determinants of dominantly inherited Alzheimer's disease. Lancet Neurology.
  6. Liu, L., Lauro, B. M., He, A., Lee, H., Bhatt, T. R., Aguilar, C. A., Liu, L., Gilberto, S., & Selkoe, D. J. (2021). Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. Brain, 144(10), 2939–2945.
  7. Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016). Alzheimer's disease. The Lancet, 388(10043), 505–517.
  8. Griffiths, J., & Spires-Jones, T. L. (2023). Synaptic degeneration in Alzheimer disease. Nature Reviews Neurology, 19, 19–38.
  9. Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022). Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature Medicine, 28(11), 2381–2387.
  10. Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New England Journal of Medicine, 367(9), 795–804.
  11. Quiroz, Y. T., Sperling, R. A., Norton, D. J., Baena, A., Arboleda-Velasquez, J. F., Cosio, D., Schultz, A., Lapoint, M., Guzmán-Vélez, E., Miller, J. B., et al. (2018). Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurology, 75(5), 548–556.
  12. Quiroz, Y. T., Aguillon, D., Aguirre-Acevedo, D. C., Vasquez, D., Zuluaga, Y., Baena, A. Y., Madrigal, L., Hincapié, L., Sanchez, J. S., Langella, S., et al. (2024). APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's disease. New England Journal of Medicine, 390(23), 2156–2164.
  13. Biel, D., Brendel, M., Rubinski, A., Buerger, K., Janowitz, D., Dichgans, M., & Franzmeier, N. (2021). Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimer's Research & Therapy, 13(1), 137.
  14. Mah, D., Zhao, J., Liu, X., Zhang, F., Liu, J., Wang, L., Linhardt, R., & Wang, C. (2021). The sulfation code of tauopathies: heparan sulfate proteoglycans in the prion-like spread of tau pathology. Frontiers in Molecular Biosciences, 8, 671458.
  15. Wang, Y., Balaji, V., Kaniyappan, S., Krüger, L., Irsen, S., Tepper, K., Chandupatla, R., Maetzler, W., Schneider, A., Mandelkow, E., & Mandelkow, E.-M. (2017). The release and trans-synaptic transmission of tau via exosomes. Molecular Neurodegeneration, 12(1), 5.
  16. Perez, M., Avila, J., & Hernandez, F. (2019). Tau secretion. Advances in Experimental Medicine and Biology, 1184, 247–256.
  17. Windham, I. A., & Cohen, S. (2024). The cell biology of APOE in the brain. Trends in Cell Biology, 34(4), 338–348.
  18. Chen, Y., Song, S., Parhizkar, S., Lord, J., Zhu, Y., Strickland, M. R., Wang, C., Park, J., Tabor, G. T., Jiang, H., et al. (2024). APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread. Cell, 187(2), 428–445.
  19. Zhao, J., Zhu, Y., Song, X., Xiao, Y., Su, G., Liu, X., Wang, Z., Xu, Y., Liu, J., Eliezer, D., et al. (2020). 3-O-sulfation of heparan sulfate enhances tau interaction and cellular uptake. Angewandte Chemie International Edition, 59(5), 1818–1827.
  20. Ferreira, A., Royaux, I., Liu, J., Wang, Z., Su, G., Moechars, D., Callewaert, N., & De Muynck, L. (2022). The 3-O sulfation of heparan sulfate proteoglycans contributes to the cellular internalization of tau aggregates. BMC Molecular and Cell Biology, 23(1), 61.
  21. Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024). Microglial APOE3 Christchurch protects neurons from tau pathology in a human iPSC-based model of Alzheimer's disease. Cell Reports, 43(12), 114982.
  22. Gratuze, M., Chen, Y., Parhizkar, S., Jain, N., Strickland, M. R., Remolina Serrano, J., Colonna, M., Ulrich, J. D., & Holtzman, D. M. (2021). Activated microglia mitigate Aβ-associated tau seeding and spreading. Journal of Experimental Medicine, 218(8), e20210542.
  23. Lopera, F., Marino, C., Chandrahas, A. S., O'Hare, M., Villalba-Moreno, N. D., Aguillon, D., Baena, A., Sanchez, J. S., Vila-Castelar, C., Ramirez Gomez, L., et al. (2023). Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man. Nature Medicine, 29(5), 1243–1252.
  24. Cochran, J. N., Greicius, M. D., & Goate, A. M. (2024). APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's disease. New England Journal of Medicine, 391(17), 1660–1661.